Literature DB >> 25616060

The NF-κB regulator Bcl-3 modulates inflammation during contact hypersensitivity reactions in radioresistant cells.

Ilaria Tassi1, Nimisha Rikhi1, Estefania Claudio1, Hongshan Wang1, Wanhu Tang1, Hye-Lin Ha1, Sun Saret1, Daniel H Kaplan2, Ulrich Siebenlist1.   

Abstract

Bcl-3 is an atypical member of the IκB family. Bcl-3 functions as a cofactor of p50/NF-κB1 or p52/NF-κB2 homodimers in nuclei, where it modulates NF-κB-regulated transcription in a context-dependent way. Bcl-3 has tumorigenic potential, is critical in host defense of pathogens, and has been reported to ameliorate or exacerbate inflammation, depending on disease model. However, cell-specific functions of Bcl-3 remain largely unknown. Here, we explored the role of Bcl-3 in a contact hypersensitivity (CHS) mouse model, which depends on the interplay between keratinocytes and immune cells. Bcl-3-deficient mice exhibited an exacerbated and prolonged CHS response to oxazolone. Increased inflammation correlated with higher production of chemokines CXCL2, CXCL9, and CXCL10, and consequently increased recruitment of neutrophils and CD8(+) T cells. BM chimera experiments indicated that the ability of Bcl-3 to reduce the CHS response depended on Bcl-3 activity in radioresistant cells. Specific ablation of Bcl-3 in keratinocytes resulted in increased production of CXCL9 and CXCL10 and sustained recruitment of specifically CD8(+) T cells. These findings identify Bcl-3 as a critical player during the later stage of the CHS reaction to limit inflammation via actions in radioresistant cells, including keratinocytes. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Bcl-3; Chemokines; Contact hypersensitivity; Keratinocytes; NF-κB

Mesh:

Substances:

Year:  2015        PMID: 25616060      PMCID: PMC4432939          DOI: 10.1002/eji.201444994

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  36 in total

1.  Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade.

Authors:  Ruaidhrí J Carmody; Qingguo Ruan; Scott Palmer; Brendan Hilliard; Youhai H Chen
Journal:  Science       Date:  2007-08-03       Impact factor: 47.728

Review 2.  Shared principles in NF-kappaB signaling.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

3.  Functional redundancy of Langerhans cells and Langerin+ dermal dendritic cells in contact hypersensitivity.

Authors:  Madelon Noordegraaf; Vincent Flacher; Patrizia Stoitzner; Björn E Clausen
Journal:  J Invest Dermatol       Date:  2010-08-12       Impact factor: 8.551

4.  Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis.

Authors:  Daniel Kreisel; Seiichiro Sugimoto; Jeremy Tietjens; Jihong Zhu; Sumiharu Yamamoto; Alexander S Krupnick; Ruaidhri J Carmody; Andrew E Gelman
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

5.  Bcl-3 acts as an innate immune modulator by controlling antimicrobial responses in keratinocytes.

Authors:  Amanda S Büchau; Daniel T MacLeod; Shin Morizane; Paul F Kotol; Tissa Hata; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2009-03-12       Impact factor: 8.551

6.  Cutaneous hypersensitivities to hapten are controlled by IFN-gamma-upregulated keratinocyte Th1 chemokines and IFN-gamma-downregulated langerhans cell Th2 chemokines.

Authors:  Tomoko Mori; Kenji Kabashima; Ryutaro Yoshiki; Kazunari Sugita; Noriko Shiraishi; Ayako Onoue; Etsushi Kuroda; Miwa Kobayashi; Uki Yamashita; Yoshiki Tokura
Journal:  J Invest Dermatol       Date:  2008-01-31       Impact factor: 8.551

7.  Langerhans cells suppress contact hypersensitivity responses via cognate CD4 interaction and langerhans cell-derived IL-10.

Authors:  Botond Z Igyarto; Matthew C Jenison; Jan C Dudda; Axel Roers; Werner Müller; Pandelakis A Koni; Daniel J Campbell; Mark J Shlomchik; Daniel H Kaplan
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

8.  Roles of Bcl-3 in the pathogenesis of murine type 1 diabetes.

Authors:  Qingguo Ruan; Shi-Jun Zheng; Scott Palmer; Ruaidhri J Carmody; Youhai H Chen
Journal:  Diabetes       Date:  2010-07-09       Impact factor: 9.461

9.  Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men.

Authors:  Milena Bogunovic; Florent Ginhoux; Amy Wagers; Martine Loubeau; Luis M Isola; Lauren Lubrano; Vesna Najfeld; Robert G Phelps; Celia Grosskreutz; Eilleen Scigliano; Paul S Frenette; Miriam Merad
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

10.  Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cells.

Authors:  Daniel H Kaplan; Ming O Li; Matthew C Jenison; Warren D Shlomchik; Richard A Flavell; Mark J Shlomchik
Journal:  J Exp Med       Date:  2007-10-15       Impact factor: 14.307

View more
  4 in total

1.  LncRNA CRNDE affects the proliferation and apoptosis of vascular smooth muscle cells in abdominal aortic aneurysms by regulating the expression of Smad3 by Bcl-3.

Authors:  Kun Li; Mingzhe Cui; Kewei Zhang; Guoquan Wang; Shuiting Zhai
Journal:  Cell Cycle       Date:  2020-04-02       Impact factor: 4.534

Review 2.  The role of B-Cell Lymphoma-3 (BCL-3) in enabling the hallmarks of cancer: implications for the treatment of colorectal carcinogenesis.

Authors:  Danny N Legge; Adam C Chambers; Christopher T Parker; Penny Timms; Tracey J Collard; Ann C Williams
Journal:  Carcinogenesis       Date:  2020-05-14       Impact factor: 4.944

Review 3.  Bcl-3: A Double-Edged Sword in Immune Cells and Inflammation.

Authors:  Hui Liu; Lin Zeng; Yang Yang; Chunlei Guo; Hui Wang
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

4.  The B-cell tumor promoter Bcl-3 suppresses inflammation-associated colon tumorigenesis in epithelial cells.

Authors:  W Tang; H Wang; H L Ha; I Tassi; R Bhardwaj; E Claudio; U Siebenlist
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.